PEPVERAAUTHENTIC HIGH-QUALITY PEPTIDES
SIGN IN
Pemvidutide
CUT · XII

Pemvidutide

Phase 2 dual agonist for hepatic.

From / per milligram
$40$—/mg · 5MG
Sizes available
—
Lab certificate (COA)
Arrives with shipment
View test certificate →

· Research-grade only · Not for human consumption · 21+ ·

What is it

Dual GLP-1 + glucagon. For MASH (liver fat) and obesity. Phase 2.

Mechanism · Altimmune dual-agonist. Phase 2 NASH / obesity (NCT05295875).

Who

Best for. Not for.

Best for

  • Dual indication of MASH (fatty liver) plus obesity.
  • Comfortable trying an Altimmune Phase 2 compound.
  • Want the GLP-1 + glucagon synergy.

Not for

  • GLP-1 and glucagon class warnings.
  • Active hepatic decompensation.
  • Pregnancy, nursing, or type 1 diabetes.
  • Still Phase 2. No FDA approval and no long-term data.
What it does

Mechanism, dose, ramp, risk.

Mechanism
Dual GLP-1 + glucagon. Studied for MASH (NAFLD).Source · PEPVERA editorial
Target dose
Research only.Source · PEPVERA editorial
Ramp
Slow weekly.Source · PEPVERA editorial
Risks
Trial-stage data only.Source · PEPVERA editorial
Alternatives

Compared to its siblings.

★ Currently viewing

Pemvidutide

Dual GLP-1 + glucagon. For MASH (liver fat) and obesity. Phase 2.

Pros

  • · Stronger MASH-specific Phase 2 data than retatrutide.
  • · No glucagon-arm gap vs tirzepatide; better liver-fat reduction.

Cons

  • · Lower Phase 2 weight loss than retatrutide (~15.6% vs ~24%).
  • · Survodutide reports deeper liver-fat reduction (~83%) in MASH.
  • · No FDA approval or insurance coverage, unlike tirzepatide.

Survodutide

Similar dual GLP-1 + glucagon. BI Phase 2 / 3.

Pros

  • · MASH liver-fat reduction ~83%.

Cons

  • · Still BI Phase 2 / 3.

See Survodutide →

Retatrutide

Triple receptor (+GIP). Stronger Phase 2 weight loss.

Pros

  • · ~24% Weight loss.

Cons

  • · Less MASH-specific data.

See Retatrutide →

Tirzepatide

FDA approved. Broader real-world experience.

Pros

  • · FDA 2022 with insurance coverage.

Cons

  • · No glucagon arm. Weaker liver-fat reduction.

See Tirzepatide →

How we verify

COA per supplier

Published, in-house, or shipment-time

Each supplier declares its own HPLC floor and COA policy. The per-supplier verifier appears on the certificate page; refund and shipping terms vary by supplier and are shown on the supplier listing.

→ How we verify suppliers→ Refund policy
Fat lossMetabolicGLP-1GlucagonExperimentalresearch-only
Suppliers

Compare 0 suppliers

No verified suppliers yet for this compound.

❄ COLD-CHAIN · 5–9 DAYS

Direct from foundry. Slower than domestic resellers; consistency is the trade. Insulated packaging, tracked from departure to doorstep. Replacement issued on damage.

Before you begin

Risk

Trial-stage data only. These pass with discipline. They do not pass with bravado.

Source · PEPVERA editorial

Discipline

Slow weekly.

Source · PEPVERA editorial

Wellness

Hydrate. Eat protein. Sleep eight. Hold a dose for at least two weeks before ascending.

Anti-patterns

  • · Do not pair with stimulants late in the day.
  • · Do not break the cycle without a planned taper.
  • · Do not exceed the dose to chase a deeper sleep response.

Crisis

If the ramp triggers severe anxiety, anhedonia, or persistent gastrointestinal disturbance, stop. Resume after two weeks at half the prior dose. The discipline is the slow climb.

Dosing protocol

Week 1–2

0.25 mg / wk

Baseline ramp

Week 3–4

0.5 mg / wk

Hold, observe

Week 5–8

1.0–2.0 mg / wk

Ascend

Week 9–12

Research only.

Terminus

Reconstitution

Draw 20 units.

0.5 mg = 0.20 mL at 2.50 mg/mL. 10.0 doses per vial.

cut · XII

Pemvidutide · 5mg